Anifrolumab yielded positive outcomes, including remission in 26% of patients, at 6 months across a real-word, multicenter cohort of patients with systemic lupus erythematosus, according to data ...

INDIANAPOLIS (WISH) — Lupus is a debilitating autoimmune disease that affects around 1.5 million Americans. Now, new research shows a therapy that’s been used for cancer patients may help people with ...

InvestigateTV+ shares a young mother’s struggle with the debilitating effects of lupus. Plus, we take an in-depth look at what could become a breakthrough treatment.

Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not ...

The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer ...

Please provide your email address to receive an email when new articles are posted on . Pancytopenia occurred in more than 13% of patients with systemic lupus erythematosus receiving immune checkpoint ...

But one doctor after another failed to make the connection. She was told by one it was stress related and she should quit her job. Another congratulated her on the weight loss and said how much ...

AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in ...

Short-term observational data support belimumab as a safe therapeutic option in patients with lupus nephritis, who are at increased risk of cancer. Over the short term, overall cancer risk may be ...

Jennifer Le’s doctor ticked through a long checklist of head-to-toe symptoms as she examined Le in a Boston clinic last month. Was she experiencing brain fog? Headaches? What about hair loss, rashes ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.